Eureka Therapeutics

What Eureka Therapeutics does

Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Emeryville, California, developing T-cell therapies for solid tumors and hematologic malignancies. The company's technology is built on two proprietary platforms: the E-ALPHA phage display platform, one of the world's largest human-derived antibody libraries with over 100 billion unique clones used to discover cancer-specific antibodies including TCR-mimic antibodies against intracellular antigens, and the ARTEMIS cell receptor platform, which engineers T cells with an antibody-T-cell receptor (AbTCR) architecture and a separate co-stimulatory molecule designed to reduce cytokine release syndrome and neurotoxicity versus conventional CAR-T while improving tumor infiltration and persistence. The clinical pipeline is anchored by ET140203 (an AFP-targeting ARTEMIS T-cell therapy in ARYA-1/ARYA-2 Phase I/II trials for adult and pediatric liver cancer) and ECT204 (a GPC3-targeting ARTEMIS CAR-T in ARYA-3 Phase I/II for advanced HCC, FDA RMAT-designated in January 2026), with additional discovery and preclinical programs across multiple myeloma, B-cell lymphoma, and other solid tumor indications including pancreatic, ovarian, breast, glioblastoma, and lung cancers.

The company's business model is pre-commercialization. Revenue, where present, is generated through licensing agreements, milestone payments, and royalties from pharmaceutical partners — including exclusive licenses to Juno Therapeutics (BCMA, MUC16), Sanofi (GPRC5D for multiple myeloma, eligible for over $1 billion in potential milestones), Boehringer Ingelheim (TCR-mimic option), and a strategic collaboration with Lyell Immunopharma (which also led the $45M Series E in March 2020). The company also out-licensed ARTEMIS for China and ASEAN markets to JW Therapeutics via Syracuse Biopharma. Eureka has raised approximately $140M in cumulative equity and grant funding and operates with 51-100 employees. Customers in the near term are oncology centers and clinical trial sites participating in multi-center Phase I/II trials, while the end therapeutic customer base is cancer patients with advanced solid tumors (particularly HCC) and hematologic malignancies who have exhausted standard-of-care options. Distribution of approved therapies is expected to follow traditional specialty pharmacy and hospital pharmacy channels.

Name

Eureka Therapeutics

Legal name

Eureka Therapeutics, Inc.

Website

https://eurekatherapeutics.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

Eureka Therapeutics is a clinical-stage biotechnology company developing ARTEMIS and E-ALPHA platform-based T-cell therapies for solid tumors and hematologic malignancies, with two lead programs (ET140203, ECT204) in Phase I/II liver cancer trials.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy / T-Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• T-cell therapy
• Cancer immunotherapy
• Cell receptor platform
• Antibody phage display
• Clinical biopharmaceuticals

Headquarters

HQ city

Emeryville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel

Revenue model

1. T-cell Therapy Development and Commercialization: As a clinical-stage biopharmaceutical company, Eureka Therapeutics is developing T-cell therapies for cancer treatment. The company has two ARTEMIS-based clinical programs (ET140203 and ECT204) in Phase I/II trials for advanced liver cancer. Revenue will be generated through commercialization of approved therapies upon successful clinical development and regulatory approval.
2. Licensing and Milestone Payments: The company generates revenue through licensing agreements with pharmaceutical partners. Notable agreements include partnerships with Sanofi (GPRC5D, potential $1B+ in milestones), Juno Therapeutics (BCMA, multiple myeloma targets), and others. These arrangements provide upfront payments, development milestones, regulatory milestones, and sales royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Eureka Therapeutics is a clinical-stage biopharmaceutical company that develops investigational autologous T-cell therapies for solid tumors and hematologic malignancies, built on two proprietary platforms: the E-ALPHA® antibody phage display platform and the ARTEMIS® cell receptor platform. Its lead clinical programs ET140203 (AFP-targeting) and ECT204 (GPC3-targeting) are in Phase I/II trials for adult and pediatric hepatocellular carcinoma, with revenue generated through licensing of platform technology and binding domains to pharmaceutical partners.

Product overview

Eureka Therapeutics is a clinical-stage biopharmaceutical company developing transformative T-cell therapy platforms and candidates for the treatment of solid tumors and hematologic malignancies. Its core product portfolio is built on two proprietary technology platforms: the E-ALPHA® Phage Display Platform (one of the world's largest human-derived antibody phage libraries, over 100 billion clones) for discovering cancer-specific antibodies including TCR-mimic antibodies, and the ARTEMIS® Cell Receptor Platform (incorporating AbTCR and co-stimulatory molecule) for engineering T cells. The company's clinical pipeline includes ET140203 (an AFP-targeting ARTEMIS T-cell therapy in ARYA-1/ARYA-2 trials for adult and pediatric liver cancer) and ECT204 (a GPC3-targeting ARTEMIS CAR T-cell therapy in ARYA-3 trial for adult liver cancer, RMAT-designated). Discovery-stage programs target antigens including ROR1, MSLN, CD19, GPC2, WT1, BCMA, GPRC5D, and BCMA/GPRC5D across solid tumors and multiple myeloma. The company also offers EurekaConnectMe, a patient portal for clinical trial enrollment.

Differentiator

Problem solved

Functional benefit

Brands

• ARTEMIS: Proprietary cell receptor platform technology for T-cell therapy combining antibody-based target recognition with gamma/delta TCR signaling.
• E-ALPHA

Products and services

• E-ALPHA® Phage Display Platform Proprietary antibody discovery platform (Eureka Adaptive Library Panning for Human Antibodies) consisting of one of the world's largest human-derived antibody phage libraries with over 100 billion unique antibody clones. Used to generate highly specific antibodies against cancer-specific targets, including TCR-mimic antibodies against intracellular targets previously considered undruggable. Licensed to pharmaceutical partners for antibody discovery collaborations.
• ARTEMIS® Cell Receptor Platform Proprietary T-cell receptor platform (Antibody Redirected T Cells with Endogenous Modular Immune Signaling) using an AbTCR architecture that combines Fab-based antigen recognition with gamma/delta TCR signaling and a separate co-stimulatory molecule. Designed to reduce cytokine release syndrome and neurotoxicity, enhance tumor infiltration, and improve T-cell persistence versus conventional CAR-T. Licensed to partners including JW Therapeutics for China and ASEAN rights.
• ARTEMIS® T-Cell Therapy Investigational autologous T-cell therapy in which patient T cells are collected, engineered to express ARTEMIS cell receptors (AbTCR and co-stimulatory molecule), expanded, and cryopreserved for delivery to patients. Designed to seek out, bind to, and destroy target-positive cancer cells with enhanced tumor infiltration and reduced cytokine release syndrome risk. Administered through multi-center Phase I/II clinical trial sites.
• ET140203 Investigational autologous ARTEMIS T-cell therapy expressing a TCR-mimic antibody targeting the alpha-fetoprotein (AFP)-peptide/HLA-A2 complex on liver cancer cells. Currently in Phase I/II ARYA-1 (adult) and ARYA-2 (pediatric) trials for hepatocellular carcinoma and hepatoblastoma; FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations granted.
• ECT204 Investigational autologous ARTEMIS CAR T-cell therapy targeting Glypican-3 (GPC3), an oncofetal antigen expressed on more than 70% of HCC cells. Currently in Phase I/II ARYA-3 clinical trial in adult patients with GPC3-positive advanced HCC; FDA Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation granted in January 2026.
• EurekaConnectMe Online patient portal providing information on Eureka Therapeutics' multi-center Phase I/II U.S. clinical trials evaluating T-cell therapies for the treatment of cancer, enabling patients to learn about and potentially enroll in ongoing trials.

Quantifiable outcome

• 16-fold greater tumor infiltration (54% vs 3% of T cells within tumors) compared to conventional CAR-T in NCI-led preclinical studies
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and major.

• ImugenecoreStrategic or Co-development Partner · 1 November 2021Strategic collaboration combining Eureka's anti-CD19 ARTEMIS T-cell therapy with Imugene's CD19-expressing oncolytic virus onCARlytics for solid tumors. This 'mark and kill' approach forces tumors to express CD19, enabling T-cell targeting. Preclinical studies showed complete cures in mice models.
• SanoficoreTechnology or Integration · 6 July 2021License agreement for non-CAR use of novel human binding domain targeting GPRC5D for multiple myeloma treatment. Eureka and MSK eligible to receive over $1 billion in potential milestone payments plus tiered royalties on net sales.
• JW TherapeuticscoreTechnology or Integration · 20 July 2020JW Therapeutics acquired Syracuse Biopharma (Hong Kong) Limited, which includes an exclusive license to Eureka's ARTEMIS antibody TCR and solid tumor technology for China and ASEAN countries. Dr. Cheng Liu joined JW Therapeutics' Board of Directors.
• Lyell ImmunopharmacoreStrategic or Co-development Partner · 17 March 2020Strategic collaboration to develop therapies against several undisclosed solid tumor targets. Eureka received $45 million Series E financing led by Lyell. Dr. Rick Klausner, Lyell's Founder and CEO (also co-founder of Juno Therapeutics and former NCI Director), expressed confidence in the TCR-mimic and ARTEMIS technologies.
• Juno TherapeuticscoreTechnology or Integration · 4 August 2016Exclusive license agreement with MSK and Eureka for novel human binding domain targeting BCMA and two additional undisclosed multiple myeloma targets for CAR T cell immunotherapy. Parties eligible for upfront, clinical, regulatory, and commercial milestone payments plus royalties.
• Juno TherapeuticscoreTechnology or Integration · 7 January 2016Exclusive license agreement between MSK and Juno for fully-human MUC16 binding domain for CAR cell therapy in ovarian, fallopian tube, and primary peritoneal cancers. Binder developed under Eureka-MSK collaboration.
• Boehringer IngelheimmajorStrategic or Co-development Partner · 21 May 2015Research collaboration for discovery of novel therapeutic antibodies targeting intracellular oncogenes (~90% of cancer-specific targets). Eureka received undisclosed upfront fees, research funding, and potential milestone payments. Boehringer Ingelheim has option for further development and commercialization.
• Memorial Sloan Kettering Cancer Center (MSKCC)coreStrategic or Co-development PartnerLong-standing collaboration for development of TCR-mimic antibodies and ARTEMIS T-cell therapies. Multiple joint programs including AFP, GPC3, BCMA, GPRC5D, WT1, MUC16 targets. Dr. David Scheinberg (MSKCC) serves on Eureka's Scientific Advisory Board.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerNCI-led research published in Cell Reports Medicine demonstrated ARTEMIS CAR T cells significantly outperformed conventional CAR T in preclinical solid tumor models. Collaboration advancing ARTEMIS platform into additional solid tumor types including pancreatic, mesothelioma, ovarian, breast, glioblastoma, and lung cancers.
• City of Hope Comprehensive Cancer CentermajorStrategic or Co-development PartnerPreclinical collaboration demonstrating combination of CAR-T with oncolytic virus eliminated solid tumors in mice. Dr. Yuman Fong from City of Hope serves on Eureka's Scientific Advisory Board. City of Hope developed the CF33-CD19 oncolytic virus technology.
• Estrella ImmunopharmamajorTechnology or IntegrationEstrella Immunopharma (Eureka's subsidiary/parent) is developing EB103, a CD19-redirected ARTEMIS T-cell therapy for aggressive B-cell Non-Hodgkin Lymphoma. Phase 1 STARLIGHT-1 data to be presented at 2026 ASTCT & CIBMTR Tandem Meetings. EB104 targeting both CD19 and CD22 also in development.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR-T cell therapies targeting solid tumors (including SPEAR T-cells for MAGE-A4, AFP, and other antigens). Highly comparable to Eureka's TCR-based solid tumor approach, with similar Phase I/II trial designs and HLA-restricted target strategy.
• Allogene Therapeutics: Clinical-stage company developing allogeneic (off-the-shelf) CAR-T cell therapies for both hematologic malignancies and solid tumors. Comparable as a clinical-stage cell therapy peer with multiple oncology programs and a focus on next-generation engineered T-cell platforms.
• Caribou Biosciences: Clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR gene editing, including programs for hematologic malignancies and solid tumors. Comparable engineered T-cell platform peer with similar clinical-stage profile and oncology focus.
• Iovance Biotherapeutics: Commercial-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, with FDA-approved Amtagvi for melanoma. Comparable as a T-cell-based therapy company targeting solid tumors and addressing the same tumor microenvironment challenges.
• CRISPR Therapeutics: Clinical-stage gene-editing company developing CRISPR/Cas9-edited CAR-T therapies (e.g., CTX112 for B-cell malignancies) and gene therapies. Comparable as a clinical-stage engineered cell therapy peer with similar platform-based development approach and oncology focus.
• Atara Biotherapeutics: Clinical-stage company developing allogeneic T-cell therapies, including EBV-specific T-cells and next-generation CAR-T programs. Comparable as a clinical-stage T-cell therapy peer with oncology focus and similar regulatory designations strategy.
• Cellectis: Clinical-stage gene-editing company developing TALEN-edited allogeneic CAR-T cell therapies (e.g., UCART19). Comparable engineered T-cell platform peer with similar clinical-stage profile and oncology indication overlap.
• Fate Therapeutics: Clinical-stage cell therapy company developing off-the-shelf iPSC-derived NK and T-cell therapies for cancer. Comparable as a clinical-stage engineered cell therapy peer with multiple oncology programs and platform-based development approach.

Broad incumbents

• Lyell Immunopharma: Clinical-stage T-cell therapy company focused on solid tumors, led by Dr. Rick Klausner (former NCI Director, Juno co-founder). Lead investor in Eureka's Series E and strategic collaboration partner. Comparable as a larger, well-funded T-cell therapy peer with overlapping solid tumor focus.
• Gilead Sciences (Kite): Large biopharmaceutical company with a leading CAR-T franchise (Yescarta, Tecartus) through its Kite subsidiary. Comparable as a broader incumbent in cell therapy with significantly greater resources and commercial infrastructure, pursuing solid tumor expansion.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/eurekathera
• YouTubeyoutube.com/c/EurekaTherapeutics
• Facebookfacebook.com/eurekatherapeutics
• LinkedInlinkedin.com/company/eureka-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eureka Therapeutics